# KISQALI® (ribociclib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ribociclib

> The FDA approved KISQALI® (ribociclib), sponsored by NOVARTIS AG (NVS), on March 13, 2017.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, year only, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | KISQALI® (ribociclib) |
| Codes | LEE011 |
| Sponsor | NOVARTIS AG (NVS) https://sec-api.dev/companies/nvs/catalysts |
| Indications | [Early Breast Cancer](https://sec-api.dev/indications/early-breast-cancer), [Melanoma](https://sec-api.dev/indications/melanoma) |
| Modality | small_molecule |
| FDA designations | priority review |

## Timeline

### March 13, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209092 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170313, review_priority PRIORITY; sponsor_name NOVARTIS; product KISQALI (RIBOCICLIB SUCCINATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209092%22

### July 6, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209092 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20200706, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI (RIBOCICLIB SUCCINATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209092%22

### December 10, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209092 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20211210, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI (RIBOCICLIB SUCCINATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209092%22

### October 3, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209092 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20221003, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI (RIBOCICLIB SUCCINATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209092%22

### July 22, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209092 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20240722, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI (RIBOCICLIB SUCCINATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209092%22

### September 17, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209092 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20240917, review_priority PRIORITY; sponsor_name NOVARTIS; product KISQALI (RIBOCICLIB SUCCINATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209092%22

### 2026: topline data readout

- Status: scheduled. Date confidence: year.
- First seen 2024-12-10, last confirmed 2024-12-10.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-134759): "On track for top-line data in 2026" https://www.sec.gov/Archives/edgar/data/1750284/000095017024134759/olma-ex99_3.htm

### July 1, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209092 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20260701, review_priority PRIORITY; sponsor_name NOVARTIS; product KISQALI (RIBOCICLIB SUCCINATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209092%22

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Melanoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04417621 (Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-02 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT04417621

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Melanoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04417621 (Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-02 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT04417621

### Sep to Dec 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Early Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05827081 (Phase IIIb Study of Ribociclib + ET in Early Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05827081

### September 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Early Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05827081 (Phase IIIb Study of Ribociclib + ET in Early Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05827081

### May to Aug 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Early Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03701334 (A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-05-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT03701334

### May 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Early Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03701334 (A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-05-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT03701334

## Same indication

- [ABP-206](https://sec-api.dev/pdufa/abp-206) (AMGN)
- [Brentuximab vedotin](https://sec-api.dev/pdufa/brentuximab-vedotin) (PFE)
- [Libtayo® (cemiplimab)](https://sec-api.dev/pdufa/cemiplimab) (REGN)
- [Encorafenib](https://sec-api.dev/pdufa/encorafenib) (PFE)
- [Fianlimab](https://sec-api.dev/pdufa/fianlimab) (REGN)
- [Fianlimab+cemiplimab](https://sec-api.dev/pdufa/fianlimab-cemiplimab) (REGN)
- [RHUPH20](https://sec-api.dev/pdufa/rhuph20) (BMY)

Calendar months: [February 2027](https://sec-api.dev/fda-calendar/2027-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ribociclib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KISQALI® (ribociclib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ribociclib

```bibtex
@misc{secapidev_pdufa_ribociclib_20261116,
  title        = {KISQALI® (ribociclib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ribociclib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ribociclib_20261116","title":"KISQALI® (ribociclib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ribociclib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
